

Electronic Acknowledgement Receipt

EFS ID:	3181974
Application Number:	10572671
International Application Number:	
Confirmation Number:	4589
Title of Invention:	Piperazinyl-quinoline derivatives useful for the treatment of cns disorders
First Named Inventor/Applicant Name:	Christopher Norbert Johnson
Customer Number:	20462
Filer:	Kathryn Lutomski Sieburth/Mary Fenerty
Filer Authorized By:	Kathryn Lutomski Sieburth
Attorney Docket Number:	PB60516
Receipt Date:	21-APR-2008
Filing Date:	20-MAR-2006
Time Stamp:	14:14:48
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	9278
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1		Amendment.pdf	255120	yes	8
			3c912ad25a738dc2ca31e411bceee05a5ac59b059		
Multipart Description/PDF files in .zip description					
Document Description		Start	End		
Amendment - After Non-Final Rejection		1	1		
Specification		2	2		
Claims		3	5		
Applicant Arguments/Remarks Made in an Amendment		6	7		
Abstract		8	8		
Warnings:					
Information:					
2		IDSand1449.pdf	130737	yes	3
			620d5961e33140501dffe60d1a41dbd5c27045a		
Multipart Description/PDF files in .zip description					
Document Description		Start	End		
Information Disclosure Statement Letter		1	2		
Information Disclosure Statement (IDS) Filed		3	3		
Warnings:					
Information:					
3	Foreign Reference	1WO2003080580A2.pdf	2275381	no	48
			7f0349b61d21b093b7a205cab17e699058413ac204		
Warnings:					
Information:					

4	Foreign Reference	2WO2003035061A1.pdf	947044 545c3e6a74960b44f76ab3e0db57b5 0ffdb322	no	32
Warnings:					
Information:					
5	NPL Documents	3Woolley_Neuropharm_2001.pdf	258731 a3da274db2022aeeb676e1ac016a75a 87c8788d	no	10
Warnings:					
Information:					
6	NPL Documents	4Mitchell_Pharmacol_Ther_2005.pdf	2006749 bu1175af9da3e522390207c45aa3d5 7d2571f	no	14
Warnings:					
Information:					
7	NPL Documents	5Chuang_Alz_Dementia.pdf	594503 46cd44f01563511da3cf7143e7ce032 b853b6e	no	5
Warnings:					
Information:					
8	NPL Documents	6London_SE_Announcemen t_2007.pdf	329366 da949c4359285abd05c9c522978b078 6246329	no	4
Warnings:					
Information:					
9	NPL Documents	7Dose_Ranging_Study_SB7 42457_2007.pdf	131689 d803128045ab8d0de103ab0c875e0da 4db2c5690	no	4
Warnings:					
Information:					
10	NPL Documents	8SB742457_Donepezil_AD_2006.pdf	130389 25a59cd56786187a2b0c1602c83287 8479c21b4	no	4
Warnings:					
Information:					
11	NPL Documents	9Garcia_Alloza_Neuropsych opharm_2004.pdf	1039342 e068789af80f5d4513d93ba4764f76c4f 743b0d	no	7
Warnings:					
Information:					
12	Fee Worksheet (PTO-06)	fee-info.pdf	8241 5d1ef1bae7a5bdc056ce19d5d34f4412 6c4da92	no	2
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.